Low dosage liposomal amphotericin B in the treatment of Candida infections in critically ill patients. 2011

M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D016638 Critical Illness A disease or state in which death is possible or imminent. Critically Ill,Critical Illnesses,Illness, Critical,Illnesses, Critical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
June 2012, Journal of clinical pharmacy and therapeutics,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
June 1997, Antimicrobial agents and chemotherapy,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
October 2022, Medical mycology,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
January 2017, PloS one,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
June 2009, Journal of chemotherapy (Florence, Italy),
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
July 1986, Annals of internal medicine,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
May 2020, BMJ case reports,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
August 2015, Critical care medicine,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
May 2015, Intensive care medicine,
M Bassetti, and E Blasi, and A Giarratano, and F G DE Rosa, and L Balzano, and C Viscoli
September 2012, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Copied contents to your clipboard!